Biodexa Pharmaceuticals PLC
BDRX
Company Profile
Business description
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Contact
1 Caspian Point
Caspian Way
CardiffCF10 4DQ
GBRT: +44 2920480180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,887.60 | 17.10 | 0.19% |
| CAC 40 | 7,980.81 | 91.32 | -1.13% |
| DAX 40 | 23,869.07 | 85.49 | -0.36% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,232.25 | 19.14 | 0.19% |
| HKSE | 25,770.67 | 341.17 | -1.31% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,284.92 | 632.54 | -1.06% |
| NZX 50 Index | 12,903.31 | 133.01 | 1.04% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,665.80 | 25.60 | 0.30% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |